Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 8,250 KRW
Change Today +1,070 / 14.90%
Volume 3.4M
009420 On Other Exchanges
Symbol
Exchange
Korea SE
As of 2:10 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

hanall biopharma co ltd (009420) Snapshot

Open
7,400
Previous Close
7,180
Day High
8,250
Day Low
7,400
52 Week High
05/29/15 - 8,250
52 Week Low
06/25/14 - 3,555
Market Cap
344.9B
Average Volume 10 Days
1.1M
EPS TTM
-314.00
Shares Outstanding
41.8M
EX-Date
12/29/09
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HANALL BIOPHARMA CO LTD (009420)

Related News

No related news articles were found.

hanall biopharma co ltd (009420) Related Businessweek News

No Related Businessweek News Found

hanall biopharma co ltd (009420) Details

HanAll BioPharma Co., Ltd., a biopharmaceutical company, researches and develops biopharmaceutical products worldwide. It develops H176 and HL177, a series of anti-cancer agents for cancer metabolism; and HL156FIB, an EMT inhibitor for fibrotic diseases, such as IPF, peritoneal fibrosis, hypertrophic scar, etc. The company also develops products for infectious diseases, such as HL143, a single amino acid variant of native IFN-alpha-2a; and Hanferon, a protease resistant for genotype 1 hepatitis C patients. In addition, it provides HL036, a TNF-alpha receptor fragment for the treatment of inflammatory diseases caused by TNF-alpha, such as uveitis, dry eyes, and AMD. Further, the company offers HL161, an anti-FcRn mAb for the treatment of autoimmune diseases caused by IgG auto antibodies and immune complex mediated glomerular diseases; and HL009, an adenosylcobalamin liposomal gel in the area of immunology diseases. Additionally, it provides Vitatropin, an oral human growth hormone, as well as HL-178, a negative regulator of TXNIP in the area of endocrinology diseases; and HL040, a combination of atorvastatin and losartan for the treatment of cardiovascular disease, such as hypertension and hyperlipidemia. The company also exports its products. HanAll BioPharma Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

Founded in 1973

hanall biopharma co ltd (009420) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hanall biopharma co ltd (009420) Key Developments

HanAll Biopharma Co., Ltd., Annual General Meeting, Mar 27, 2015

HanAll Biopharma Co., Ltd., Annual General Meeting, Mar 27, 2015., at 10:00 Korea Standard Time. Location: 42, Songpa-gu, Seoul Baekje way mounds 5. Agenda: To consider the approval of consolidated financial statements of the constitution; to consider the appointment of directors; to consider the appointment of Audit Committee; to consider the approval of director remuneration; and to consider the approval of stock option grant.

Hanall biopharma Presents at BIO-Europe Spring 2015, Mar-09-2015

Hanall biopharma Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Hanall Biopharma Co., Ltd. Announces Earnings Results for the First Half of Fiscal Year of 2014

Hanall Biopharma Co., Ltd. announced earnings results for the first half of fiscal year of 2014. For the period, the company has turned a profit of USD 0.72 million including operation profit of USD 0.64 million over the first half of fiscal year of 2014. The company turns a profit of USD 4 million operation losses and USD 3.4 million net loss of the first half of the fiscal year of 2013 by achieving USD 37 million in revenues over the first half of fiscal year of 2014. This is estimated to be USD 3.1 million increase in revenue when compared that of the first half was USD 34 million in 2013. The company is able to turn a profit by increase in sales of selecting strategic products and business rationalization.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
009420:KS 8,250.00 KRW +1,070

009420 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 009420.
View Industry Companies
 

Industry Analysis

009420

Industry Average

Valuation 009420 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANALL BIOPHARMA CO LTD, please visit www.hanallbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.